Brokers Issue Forecasts for ALX Oncology FY2029 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – HC Wainwright issued their FY2029 earnings per share (EPS) estimates for ALX Oncology in a research note issued to investors on Friday, January 24th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of $0.63 per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group lowered shares of ALX Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. Finally, UBS Group lowered their price target on ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $3.05.

ALX Oncology Stock Performance

NASDAQ:ALXO opened at $1.53 on Monday. The firm has a market capitalization of $80.69 million, a P/E ratio of -0.51 and a beta of 0.98. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83. The company has a fifty day moving average of $1.62 and a 200-day moving average of $2.29. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Institutional Investors Weigh In On ALX Oncology

A number of hedge funds have recently modified their holdings of ALXO. AQR Capital Management LLC increased its position in ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after buying an additional 6,080 shares during the last quarter. SG Americas Securities LLC boosted its position in ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after purchasing an additional 6,888 shares during the period. Hsbc Holdings PLC purchased a new position in shares of ALX Oncology in the second quarter worth about $63,000. Wellington Management Group LLP raised its position in shares of ALX Oncology by 15.2% in the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after purchasing an additional 22,114 shares during the period. Finally, Algert Global LLC bought a new position in ALX Oncology in the 2nd quarter worth approximately $249,000. Institutional investors own 97.97% of the company’s stock.

Insider Transactions at ALX Oncology

In related news, Director Rekha Hemrajani acquired 30,000 shares of the stock in a transaction on Monday, December 2nd. The shares were acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now owns 33,000 shares in the company, valued at approximately $51,150. The trade was a 1,000.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 14,443 shares of company stock worth $23,309 in the last ninety days. Company insiders own 33.40% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.